Incyte | INCY - Stock


Incyte reported $115.62M in Stock for its fiscal quarter ending in March of 2026.





Stock Change Date
Acadia Pharmaceuticals USD 31.57M 3.1M Mar/2026
Agios Pharmaceuticals USD 35.09M 2.17M Mar/2026
Alnylam Pharmaceuticals USD 200.15M 117.43M Mar/2026
Amgen USD 6.19B 39M Mar/2026
BioCryst Pharmaceuticals USD 5.98M 587K Mar/2026
Biogen USD 1.95B 219.1M Mar/2026
BioMarin Pharmaceutical USD 1.27B 25.66M Mar/2026
Bristol-Myers Squibb USD 2.76B 66M Mar/2026
Eli Lilly USD 14.53B 785M Mar/2026
Exelixis USD 26.6M 4.92M Mar/2026
Gilead Sciences USD 1.91B 140M Mar/2026
Incyte USD 115.62M 14.56M Mar/2026
Ionis Pharmaceuticals USD 5.56M 4.49M Mar/2026
MacroGenics USD 9.5M 1.59M Mar/2026
Merck USD 6.48B 179M Mar/2026
Moderna USD 146M 7M Mar/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Neurocrine Biosciences USD 64.5M 4.5M Mar/2026
Novartis USD 6.29B 17M Mar/2026
Novartis USD 6.42B 114M Sep/2025
Pfizer USD 10.67B 13M Mar/2026
PTC Therapeutics USD 75.57M 4.08M Mar/2026
Puma Biotechnology USD 9.48M 885K Sep/2025
Regeneron Pharmaceuticals USD 3.1B 97.2M Mar/2026
Sarepta Therapeutics USD 1B 86.37M Mar/2026
Ultragenyx Pharmaceutical USD 55M 3M Mar/2026
Vertex Pharmaceuticals USD 1.77B 79.9M Mar/2026